EN DE

CARE Ratings Limited (CARERATING) Fair Value & Analysis

Financial Services · IN · Market cap ₹49.7B

CR CARE Ratings Limited CARERATING · NSE
Price₹1,688
Fair Value₹629.24
Upside-62.7%
Quality60/100
Watch CARE Ratings Limited for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Highly profitable · 36.2% net margin
Low debt · generates free cash flow
1.31% dividend yield
Mixed vs. peers (7/14)
Wide moat 79/100
Evidence: High Range ₹471.93 – ₹1,089 Share as image

Fair value as of: Aug 2, 2026

From 13 valuation models · updated 11 days ago

Share price +0.6% over the past month.

A solid business, but screening 63% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (₹1,089). The favourable scenario is already priced in.
  • Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
  • A fairly wide model range (₹471.93 to ₹1,089) leaves room in how you read the outcome.
  • For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

₹1,901 ₹362.89 Fair Value ₹629.24 Apr 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 2, 2026.

How to read this chart

60‑month range ₹362.89 – ₹1,901 · fair‑value band ₹471.93 – ₹1,089 · the ₹1,688 price screens above the ₹629.24 fair value. Dashed = 300-day average. As of Aug 2, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

CARE Ratings Limited (CARERATING) currently trades at ₹1,688, while our model-based Fair Value estimate is ₹629.24, implying the stock looks roughly 62.7% overvalued today. The Quality Score stands at 60/100 (solid quality), in the Financial Services sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, CARE Ratings Limited generated revenue of ₹4.7B at a net margin of 36.2%. Revenue grew 19.2% year over year. It earns a return on equity of 19.8%. The balance sheet holds a net cash position of ₹1.0B. Fundamentals as of Aug 2, 2026

Our scenario range runs from ₹471.93 (bear case) to ₹1,089 (bull case); at ₹1,688, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 11% below its 52-week high and 22% above its 52-week low, currently above its 200-day average. For context, the median of 10 Financial Services peers we cover trades at -53% fair-value upside, at -63%, CARERATING screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF ₹1,051 ₹1,748 ₹2,897 80
Residual Income ₹372.98 ₹488.45 ₹1,684 76
Rev-Margin DCF ₹517.72 ₹728.49 ₹972.47 74
All 13 models by family
DCF Models
Owner Earnings ₹773.73 ₹1,310 ₹2,208 31
5Y P/E Exit ₹713.26 ₹1,110 ₹1,545 38
10Y P/E Exit ₹820.64 ₹1,212 ₹1,727 35
Earnings-Based
Graham-Dodd ₹387.22 ₹1,622 ₹2,213 54
Lynch FV ₹411.37 ₹587.67 ₹763.96 50
Dividend Discount
Gordon GGM ₹178.25 ₹370.62 ₹587.94 70
DDM Multi-Stage ₹178.25 ₹312.51 ₹388.97 61
Multiples
P/E Multiple ₹555.21 ₹740.28 ₹925.34 63
P/B Multiple ₹325.70 ₹434.27 ₹542.83 55
Asset-Based
NCAV (Graham) ₹155.10 ₹207.83 ₹310.19 50
Growth DCF
Growth DCF ₹1,051 ₹1,748 ₹2,897 80
Rev-Margin DCF ₹517.72 ₹728.49 ₹972.47 74
Economic Profit
Residual Income ₹372.98 ₹488.45 ₹1,684 76

Widest divergence: DCF Models (₹1,212) versus Asset-Based (₹207.83). Highest evidence: Growth DCF (80).

Notify me when CARERATING reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) ₹4.7B
Revenue growth (YoY) +19.2%
Net margin 36.2%
Return on equity 19.8%
Free cash flow ₹2.4B FY2026
P/E ratio 29.0
More key figures
Operating margin 43.6%
EPS (TTM) ₹56.87
Dividend yield 1.3%
EPS growth (YoY) +23.5%
Net cash ₹1.0B FY2026

Figures from reported company fundamentals · as of Aug 2, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 60/100

Of which business quality 61 · Market factors (momentum, volatility) 58

Profitability 64
Margins and returns on capital today
Quality Growth 38
Are margins and returns improving?
Cashflow 91
Earnings quality: real cash, not paper profit
Fin. Strength 85
Balance sheet, leverage, solvency risk
Investment 60
Disciplined investing over empire-building
Low Volatility 83
Calm price path (market factor)
Momentum 46
Price trend over the last 3–12 months (market factor)
52W Momentum 48
Distance to the 52-week high (market factor)
Net Issuance 0
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

CARE Ratings Limited, a credit rating agency, provides various rating and related services in India and internationally.

Full company description

CARE Ratings Limited, a credit rating agency, provides various rating and related services in India and internationally. It offers rating services for bank loan, debt instrument, bonds, long and short term instruments, InvITs, resolution plan, and non-convertible debentures; CDs for banks, bonds, mutual funds, and hybrid instruments; bank debt and capital market instruments, such as commercial papers, corporate bonds and debentures, and structured credit; structured finance ratings; insurance ratings; recovery ratings; issuer ratings; ratings of REITs; public finance; and monitoring agency for equity capital. The company was formerly known as Credit Analysis and Research Limited and changed its name to CARE Ratings Limited in June 2017. CARE Ratings Limited was incorporated in 1993 and is headquartered in Mumbai, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

CARE Ratings Limited reported revenue of ₹4.7B in FY2026 versus ₹2.5B in FY2022, a compound +17.6%/yr. Reported net income was ₹1.7B in FY2026, compounding +22.9%/yr from FY2022.

Growth Quality 100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2026)
₹4.7B
Latest YoY
+17.6%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+19.2%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+14.6%
Avg. growth/yr (18Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+13.1%
Revenue +17.6%/yr
FY22 ₹2.5B
FY23 ₹2.8B
FY24 ₹3.3B
FY25 ₹4.0B
FY26 ₹4.7B
Net income +22.9%/yr
FY22 ₹751M
FY23 ₹835M
FY24 ₹1.0B
FY25 ₹1.4B
FY26 ₹1.7B
Character of growth · EPS growth decomposed (2015-2026) −6.2 % p.a.
Revenue per share −2.3 pp

of which total revenue +4.3 pp · buybacks/dilution −6.5 pp

EBIT margin −6.2 pp
Tax rate +0.5 pp
Residual (interest, one-offs) +1.7 pp

Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).

CARERATING screens 63% overvalued. Compare with S&P Global Inc →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "CARE Ratings Limited Fair Value". https://www.fairvalue-calculator.com/stock/CARERATING

Peer Group

Financial Data & Stock Exchanges · 54 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 60 · Bottom 25%
Fair Value upside −63% · Bottom 25%
Return on equity (TTM) 20% · Above median
Return on assets 11% · Top 25%
Net margin (TTM) 36% · Above median
Operating margin (TTM) 44% · Above median
Revenue growth 19% · Above median
Dividend yield (TTM) 1.3% · Below median
Debt / equity 0.01× · Lower than median

Valuation Multiples vs Financial Data & Stock Exchanges median · lower = cheaper

P/E (TTM) 29.0× · Pricier than median
P/B 5.33× · Pricier than median
P/S (TTM) 10.50× · Pricier than 75% of peers
P/FCF 0.2× · Cheaper than 75% of peers
EV/EBITDA 25.5× · Pricier than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 0
FUTURE 96 · sector 69
PAST 79 · sector 77
HEALTH 100 · sector 94
DIVIDEND 26 · sector 32

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Financial Data & Stock Exchanges stocks, each showing price versus our Fair Value estimate (as of Aug 2, 2026).

Stock Price Fair Value vs Fair Value
S&P Global Inc SPGI $450.84 $196.36 -56%
CME Group CME $245.05 $145.51 -41%
Moody's Corporation MCO $504.46 $194.82 -61%
Intercontinental Exchange, Inc ICE $139.65 $75.95 -46%
Deutsche Börse AG DB1 €260.90 €142.42 -45%
Nasdaq, Inc NDAQ $88.08 $41.12 -53%
MSCI Inc MSCI $604.71 $214.91 -64%
Coinbase Global, Inc COIN $160.49 $57.05 -64%
Cboe Global Markets, Inc CBOE $273.41 $136.64 -50%
Hithink RoyalFlush Information Network Co 300033 ¥215.56 ¥55.36 -74%

Compare CARE Ratings Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Financial Services stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is CARE Ratings Limited (CARERATING) overvalued or undervalued?
As of Aug 2, 2026, our model estimates a fair value of ₹629.24 versus a price of ₹1,688, about −63% (overvalued).
What is the fair value of CARERATING?
Our model-based fair value for CARE Ratings Limited is ₹629.24 (as of Aug 2, 2026), built from audited fundamentals. The current price is ₹1,688.
What is the quality score of CARERATING?
CARE Ratings Limited has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of CARE Ratings Limited (CARERATING)?
CARE Ratings Limited reported trailing-twelve-month revenue of about ₹4.7B (latest available figure, as of Aug 2, 2026).
What is the net profit margin of CARERATING?
The net profit margin of CARE Ratings Limited is about 36.2%, meaning it keeps roughly 36.2% of revenue as net income. Based on the latest reported figures.
Does CARE Ratings Limited pay a dividend?
CARE Ratings Limited currently shows a dividend yield of about 1.31% relative to its recent price (as of Aug 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track CARE Ratings Limited and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.